Therapy of NSCLC is specifically targeted to the mentioned receptor tyrosine kinases; however, efficacy of the tyrosine kinase inhibitors may be limited by additional mutations in EGFR and compensatory activations of other pathways [210,212]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.